412 results on '"Kufe, Donald W."'
Search Results
2. MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells
3. MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer
4. Supplementary Figure 1 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
5. Supplementary Figure 3 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
6. Data from Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro
7. Data Supplement from Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro
8. Supplementary Figure 5 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
9. Supplementary Figures 1-3 from CBP501-Calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin
10. Supplementary Figure 8 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
11. Data from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
12. Supplementary Materials and Methods and Supplementary Figure Legends from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
13. Supplementary Figure 2 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
14. Manganese Superoxide Dismutase (SOD2) Inhibits Radiation-Induced Apoptosis by Stabilization of the Mitochondrial Membrane
15. Supplementary Data from Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
16. Data from Inhibition of Nuclear Factor-κB Activity by Temozolomide Involves O6-Methylguanine–Induced Inhibition of p65 DNA Binding
17. Supplementary Figure Legends 1-10 from Inhibition of Nuclear Factor-κB Activity by Temozolomide Involves O6-Methylguanine–Induced Inhibition of p65 DNA Binding
18. Supplementary Figures 1-10 from Inhibition of Nuclear Factor-κB Activity by Temozolomide Involves O6-Methylguanine–Induced Inhibition of p65 DNA Binding
19. Abstract A032: MUC1-C regulates chromatin remodeling and drives the CSC state in human cancers
20. Emergence of MUC1 in Mammals for Adaptation of Barrier Epithelia
21. Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells
22. MUC1-Induced Alterations in a Lipid Metabolic Gene Network Predict Response of Human Breast Cancers to Tamoxifen Treatment
23. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity
24. Clinical Applications of CA 15–3
25. Membrane-Derived Second Messenger Regulates X-Ray-Mediated Tumor Necrosis Factor α Gene Induction
26. Ionizing Radiation Regulates Expression of the c-jun Protooncogene
27. Increased Tumor Necrosis Factor α mRNA after Cellular Exposure to Ionizing Radiation
28. A Broadly Neutralizing Monoclonal Antibody that Recognizes the V 3 Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp120
29. Ionizing Radiation Activates Transcription of the EGR1 Gene Via CArG Elements
30. Reactive Oxygen Intermediates Target CC(A/T) 6 GG Sequences to Mediate Activation of the Early Growth Response 1 Transcription Factor Gene by Ionizing Radiation
31. The Role of Intracellular Calcium in the Cellular Response to Ionizing Radiation
32. Ionizing Radiation Down-Regulates Histone H1 Gene Expression by Transcriptional and Post-Transcriptional Mechanisms
33. Mucins in cancer: function, prognosis and therapy
34. Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma
35. Antitumor effects of fusions composed of dendritic cells and fibroblasts transfected with genomic DNA from tumor cells
36. Angiostatin potentiates cyclophosphamide treatment of metastatic disease
37. Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies
38. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion
39. Abstract 491: Encapsulation of the stem cell inhibitor Salinomycin in novel QUATRAMER sustained injectable suspension (HSB-1216) for the treatment of small cell lung cancer
40. MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment
41. Immunosuppressive milieu of high-risk localized prostate cancer.
42. Clinical Studies with Tumour Necrosis Factor
43. Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1-β-D-arabinofuranosylcytosine
44. Targeting of the MUC1-C Oncoprotein in Colitis-Associated Colorectal Cancer
45. Combined effects of angiostatin and ionizing radiation in antitumour therapy
46. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors
47. Cyclocreatine in cancer chemotherapy
48. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma
49. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents
50. Membrane-derived second messenger regulates x-ray-mediated tumor necrosis factor alpha gene induction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.